Stockwinners Market Radar for September 15, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:33 EDT VNET Group CEO Samuel Shen to resign - VNET Group "announced that Mr. Samuel Yuan-Ching Shen decided to resign from his positions as the Company's CEO and Executive Chairman of Retail IDC Business Group due to personal reasons, and he will remain with the Company as a senior advisor to the senior management. Mr. Jeff Dong, the Company's president, has been appointed to succeed Mr. Shen as the Company's Chief Executive Officer, effective immediately."

20:22 EDT Cathie Wood's ARK Investment bought 64.6K shares of CareDx today

19:30 EDT Rocket Lab exec sells $1.13M in common stock - In a regulatory filing, Rocket Lab disclosed that its EVP Shaun O'Donnell sold 200K shares of common stock on September 13th in a total transaction size of $1.13M.

18:38 EDT FedEx CEO: Demand in Asia is weak - In an interview on CNBC's Mad Money, Raj Subramaniam said what's happening in Asia is "very concerning." When factories opened after the Covid shutdown, demand did not pick up as expected, he noted. He is seeing volume declines in every segment around the world. U.S. consumers are spending more on services versus goods, he added, and he sees the U.S. slowing down. Subramaniam remains "very optimistic" on e-commerce.

18:23 EDT Gilead says WHO expands recommendation for Veklury - Gilead Sciences announced updates to the World Health Organization's Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation for Veklury's use in the treatment of patients with severe COVID-19 is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lower relative risk of death or progression to needing ventilation in patients requiring supplemental oxygen at baseline, compared to standard of care. Additionally, SOLIDARITY showed a statistically significant 13% lower relative risk of mortality with Veklury treatment for those patients hospitalized on supplemental oxygen and not requiring mechanical ventilation, compared with standard of care. In the study, Veklury had no significant effect on patients with COVID-19 who were already being ventilated. These findings complement results from the National Institute of Allergy and Infectious Diseases' double-blind placebo-controlled ACTT-1 trial, in which a mortality reduction was seen in Veklury-treated patients on low flow oxygen at baseline, as compared to placebo, in a post-hoc subgroup analysis. Veklury did not demonstrate a mortality benefit in the overall population or other baseline oxygen subgroups in either ACTT-1 or SOLIDARITY. "When the full results of SOLIDARITY were published in May 2022, it showed that Veklury reduced mortality and progression to ventilation for those patients who were oxygenated and not ventilated. These findings are consistent with other studies, such as ACTT-1," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "The WHO guideline plays an important part in informing COVID-19 treatment in many parts of the world. We are pleased this guideline update reflects the critical role that Veklury plays in helping to reduce disease progression or death from COVID-19. Veklury and generic remdesivir have been made available to more than 11 million patients around the world, and it's the only antiviral treatment recommended by the WHO for both patients at high risk of progression not requiring oxygen and those requiring supplemental oxygen."

18:11 EDT The Real Brokerage Inc. names Dre Madden as Chief Marketing Officer - The Real Brokerage Inc. announced that Dre Madden will join its executive team as Chief Marketing Officer. Madden will be responsible for driving brand awareness, increasing corporate visibility and implementing a strategic roadmap to scale the company's agent base. As a proven growth marketer, she will help expand Real's national and international footprint and increase demand generation through corporate events, field marketing and content strategy. Additionally, as Chief Marketing Officer, she will be instrumental in showcasing the company's industry-leading technology and launching future innovations in the marketplace.

17:15 EDT Methanex CEO John Floren to retire, Rich Sumner to succeed - The Board of Directors of Methanex announced that John Floren will retire as President and CEO and from the Board as of December 31, 2022. The Board has appointed Rich Sumner as President & CEO and member of the Board of Directors, effective January 1, 2023. Sumner currently holds the position of Methanex's Senior Vice President, Global Marketing & Logistics and has been with the company since 2004.

17:02 EDT Methanex board approves buyback program for 3.5M shares or 5% of outstanding - Methanex "announced that its Board of Directors has approved a Normal Course Issuer Bid whereby the Company will purchase for cancellation up to 3,506,405 common shares, representing 5% of the Shares issued and outstanding as of September 15, 2022."

16:55 EDT Black Stone Minerals CEO buys $401.6K in common stock - In a regulatory filing, Black Stone Minerals disclosed that its CEO Thomas Carter bought 24.6K shares of common stock on September 15th in a total transaction size of $401.6K.

16:52 EDT FedEx CEO 'confident' in 2025 targets despite 'disappointing' Q1 - FedEx CEO said, "Global volumes declined as macroeconomic trends significantly worsened later in the quarter, both internationally and in the U.S. We are swiftly addressing these headwinds, but given the speed at which conditions shifted, first quarter results are below our expectations. While this performance is disappointing, we are aggressively accelerating cost reduction efforts and evaluating additional measures to enhance productivity, reduce variable costs, and implement structural cost-reduction initiatives. These efforts are aligned with the strategy we outlined in June, and I remain confident in achieving our fiscal year 2025 financial targets."

16:50 EDT Four Corners Property Trust acquires three-property portfolio for $8.5M - Four Corners Property Trust "announces the acquisition of a portfolio of three properties for $8.5 million. The properties are located in a strong retail corridor in Maryland and are occupied under triple net ground leases to the corporate entities, with a weighted average remaining term of approximately eight years. The overall transaction was priced at a cap rate in range with previous FCPT transactions."

16:49 EDT FedEx falls 12% after below-consensus Q1 guidance, withdrawing FY23 outlook - Shares of FedEx are down 12% or $24.67 after the company reported preliminary Q1 earnings below consensus estimates and pulled its FY23 guidance amid volatile operating environment and expectations of further weakening in business conditions.

16:41 EDT Applied Optoelectronics jumps 34% to $3.35 after announcing sale of China assets

16:39 EDT FedEx accelerating cost reduction efforts on 'significantly worsened' trends - FedEx CEO Raj Subramaniam said, "Global volumes declined as macroeconomic trends significantly worsened later in the quarter, both internationally and in the U.S. We are swiftly addressing these headwinds, but given the speed at which conditions shifted, first quarter results are below our expectations. While this performance is disappointing, we are aggressively accelerating cost reduction efforts and evaluating additional measures to enhance productivity, reduce variable costs, and implement structural cost-reduction initiatives. These efforts are aligned with the strategy we outlined in June, and I remain confident in achieving our fiscal year 2025 financial targets." The company expects the benefits of cost actions to mitigate the effects of reduced demand throughout the remainder of fiscal 2023. These cost actions include: Reduction in flight frequencies and temporarily parking aircraft; Volume-related reductions in labor hours and other linehaul expenses; Consolidation of certain sort operations to drive productivity; Reduction of Sunday operations at a number of FedEx Ground locations; Cancellation of certain planned network capacity and other projects; Deferral of staff hiring; Closure of over 90 FedEx Office locations; and Identification of five corporate office facilities to be closed, with additional real estate rationalization planning under way.

16:32 EDT W.P. Carey increases quarterly dividend to $1.061 per share - W. P. Carey reported that its board increased its quarterly cash dividend to $1.061 per share, equivalent to an annualized dividend rate of $4.24 per share. The dividend is payable on October 14 to stockholders of record as of September 30.

16:26 EDT Rhinebeck Bancorp announces share repurchase program - Rhinebeck Bancorp announced it has adopted a program to repurchase up to 247,506 shares of its common stock, which is approximately 5% of its outstanding common stock. This is the company's first stock repurchase program since completing its mutual holding company reorganization and related stock offering in January 2019.

16:18 EDT Edgewell Personal Care streamlines leadership and organizational structure - Edgewell Personal Care Company announced organizational changes to streamline its leadership structure to support company growth. With the planned departure of Nick Powell, President of International, responsibilities for Edgewell's international business will be split between Rod Little, President and CEO, and Dan Sullivan, who will add the role of President Europe and Latin America to his CFO duties. As a part of these leadership changes, Little will lead the Japan and Greater China markets, and Sullivan will lead Europe, Latin America, Oceania and Distributor markets as well as the International Brand Strategy group, effective October 1.

16:16 EDT Jacobs says Bob Pragada to succeed Steve Demetriou as CEO - Jacobs announced a leadership succession plan that positions the company to continue driving significant profitable growth and delivering on the vision that Jacobs has set for its people, clients, communities and shareholders. Bob Pragada, currently President and COO, will succeed Steve Demetriou as CEO and join the company's Board of Directors. Demetriou will continue as Executive Chair of the Board. The changes are effective Jan. 24, 2023, the date of the company's annual shareholder meeting. Pragada joined Jacobs in 2006, holding several senior management positions over nine years. He returned to Jacobs in 2016 as President of the global Industrial and Buildings & Infrastructure lines of business, and in 2019, Pragada was appointed President and COO of Jacobs. He has been instrumental in developing and leading the successful execution of Jacobs' strategy, as well as driving global integrated delivery of Jacobs' operations around the world as a differentiator in the industry.

16:16 EDT HF Sinclair names Atanas Atanasov CFO - HF Sinclair Corporation (DINO) announced the appointment of Atanas H. Atanasov as Executive Vice President and Chief Financial Officer of HF Sinclair effective September 30, 2022, and Holly Energy Partners, L.P. (HEP) announced the appointment of Michael C. Jennings as President of Holly Logistic Services, L.L.C. effective today. HLS is the ultimate general partner of HEP. Atanasov currently serves as Chief Financial Officer of Lummus Technology LLC, a global chemical technologies company for the petrochemical and energy industries, a position he has held since April 2022. Prior to joining Lummus, Mr. Atanasov served as the Executive Vice President, Chief Financial Officer and Treasurer of Kraton Corporation, a NYSE listed specialty chemical company, from May 2019 until its merger with DL Holdings in March 2022. Prior to joining Kraton, he served as the Chief Financial Officer of Empire Petroleum Partners, LLC, a wholesale distributor of motor fuels, from February 2016 to May 2019. Prior to then, Mr. Atanasov served as Executive Vice President, Chief Financial Officer and Treasurer of NGL Energy Partners LP, a NYSE listed MLP, from May 2013 to February 2016, as Senior Vice President, Finance and Treasurer from September 2012 to May 2013 and as Vice President and Treasurer from November 2011 to September 2012. Prior to joining NGL, he held various finance roles of increasing responsibility with GE Capital from January 2003 to November 2011. He is a registered Certified Public Accountant.

16:12 EDT Applied Optoelectronics to sell China manufacturing facilities, assets for $150M - Applied Optoelectronics announced that it has entered into a definitive agreement with Yuhan Optoelectronic Technology for the sale of its manufacturing facilities located in the People's Republic of China and certain assets related to its transceiver business and multi-channel optical sub-assembly products for the internet datacenter, telecom, and FTTH markets for a purchase price of $150M, less a holdback amount. The company anticipates that the transaction will be completed in 2023 and is subject to customary closing conditions and regulatory approvals. Following the transaction, AOI will have a focused portfolio composed of lasers. Additionally, the company will retain its manufacturing facilities in Taiwan and Sugar Land, Texas. The transaction has been unanimously approved by the board of directors of the company.

16:09 EDT Gevo announces ground breaking on SAF facility - Gevo announced the groundbreaking of its first commercial-scale sustainable aviation fuel, or SAF, facility, Net-Zero 1. Gevo's management team was joined by government officials, representatives from partner companies and customers, business leaders, local farmers, and members of the media to break ground. The NZ1 project is expected to employ 1,000 people during the construction phase with approximately 90 full-time employees once operational. The facility will be constructed on 245 acres, very favorable for producing low-carbon SAF with site preparation beginning now and official construction expected to begin in 2023.

16:07 EDT Revance to present Phase 2 JUNIPER data at MDS Congress - Revance Therapeutics at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain. The presentation will include results from Revance's JUNIPER Phase 2 clinical trial evaluating the efficacy and safety of three doses of DAXXIFY compared to placebo for adults with upper limb spasticity after stroke or traumatic brain injury. DAXXIFY was found to be effective and well tolerated for treating adult ULS in the Phase 2 JUNIPER study. The duration of response observed in JUNIPER suggests that DAXXIFY has the potential to reduce the frequency of adult ULS treatments by up to 50% annually. "As an investigator in the JUNIPER trial, I am delighted to present data from JUNIPER for the first time at this year's MDS Congress," said Atul Patel, MD, and Medical Director, Kansas Institute of Research. "The data indicates that duration for DaxibotulinumtoxinA for Injection is strong and has the potential to reduce the frequency of adult upper limb spasticity treatments, delivering improvement in patients' quality of life and the opportunity to expand treatment care. With current treatments, 60% of patients report spasticity symptoms return less than 3 months after treatment. 1 The need for a new treatment option is considerable as patients have overwhelmingly indicated the desire for a longer lasting option."

16:05 EDT Applied Optoelectronics trading halted, news pending

16:02 EDT Syros, Tyme announce shareholder approval of merger - Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME's special meeting, TYME's stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022, pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros. Syros' special meeting, Syros' stockholders also voted in favor of all proposals, including the proposal to approve the issuance of shares of Syros' common stock to holders of TYME's common stock in connection with the Merger and to certain of Syros' investors in connection with a concurrent private investment in public equity financing. The closings of the Merger and the PIPE financing are anticipated to take place on or around Friday, September 16, 2022. Following the closing of the Merger, the combined company will trade on The Nasdaq Global Select Market under the ticker symbol "SYRS," and will be led by Syros' existing management team, including Nancy Simonian, M.D., Chief Executive Officer of Syros, and will remain focused on advancing Syros' pipeline of small molecule medicines for the treatment of cancer. In addition, Syros announced that it will effect a 1-for-10 reverse stock split of its common stock that will be effective on Friday, September 16, 2022, prior to the closings of the Merger and the PIPE financing. Syros' common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on Monday, September 19, 2022. The new CUSIP number for Syros' common stock following the reverse stock split is 87184Q206.

15:57 EDT SEC charges Granite $12M for fraud after former VP manipulated profit margins - The Securities and Exchange Commission charged Granite and its former senior VP, Dale Swanberg, with fraud for inflating the financial performance of the major subdivision Swanberg managed. In 2021, Granite restated its financial statements from 2017 through 2019 to correct revenue and profit margin errors allegedly caused by Swanberg's misconduct. The company agreed to pay $12M to settle the SEC's charges. In separate administrative proceedings, the company's former CEO, James Roberts, and former CFOs, Laurel Krzeminski and Jigisha Desai, while not charged with misconduct, agreed to return more than $1.4M, $327,000, and $176,000, respectively, in bonuses and compensation to Granite. These clawbacks were made pursuant to Section 304 of the Sarbanes-Oxley Act, which requires executives to reimburse certain compensation when an issuer is required to restate its financials as a result of misconduct. The SEC's complaint against Swanberg alleges that, beginning in 2017, he faced demands within Granite to turn around the flagging performance of his group and to improve its financial metrics. Swanberg and his group, however, allegedly encountered significant increases in expected costs for their construction projects that, if recorded, would have decreased the group's earned revenues. The complaint alleges that Swanberg, when faced with these competing demands, orchestrated a scheme to manipulate profit margins and improperly defer the recording of expected costs to hide the group's flagging performance. The scheme allegedly unraveled in mid-2019 when several construction projects neared completion and Swanberg could no longer defer recognition of the cost increases. Without admitting or denying the SEC's findings, Granite agreed to be enjoined from violating Section 10(b) of the Securities Exchange Act of 1934 and other provisions of the securities laws, and to pay a civil penalty of $12M. The proposed judgment is subject to court approval.

15:48 EDT Sorrento reports publication on preclinical data on COVID antibodies - Sorrento Therapeutics announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB library with neutralizing activity against SARS-CoV-2 in vitro and in vivo in Scientific Reports, a Nature portfolio journal. The full publication is available [here]:[https://rdcu.be/cVEl6]

15:00 EDT CF Acquisition Corp. VI stockholders approved combination with Rumble - CF Acquisition Corp. VI (CFVI), a special purpose acquisition company sponsored by Cantor Fitzgerald, announced that at a special meeting of the CFVI stockholders held today, CFVI's stockholders voted in favor of the proposed business combination with Rumble Inc., operator of a neutral video platform who says its mission is "to restore the Internet to its roots by making it free and open once again." As a result, the completion of the business combination is expected to occur as soon as practicable, subject the satisfaction or waiver of remaining customary closing conditions. Following the completion of the business combination, the newly combined company will operate as Rumble Inc. and trade on the NASDAQ Stock Exchange under the symbol "RUM." Assuming that closing is completed on Friday, September 16, trading will continue on NASDAQ, switching from the symbol "CFVI" to the new symbol, "RUM", at the open of trading on Monday, September 19, the company stated.

14:38 EDT Celularity announces pre-paid advance pact with Yorkville - Celularity announced that it entered into a Pre-Paid Advance Agreement with Yorkville, an affiliate of Yorkville Advisors Global. Under the agreement, Celularity may request individual pre-paid advances from Yorkville in an amount up to $40M each subject to certain conditions, up to $150M over the next eighteen months from time to time and as mutually agreed by the parties. Pre-paid advances are issued at a 2% discount, bear interest at a rate of 6% . If at any time during the 18-month commitment period there is an outstanding balance under a pre-paid advance, Yorkville may require Celularity to issue and sell shares of Common Stock to Yorkville at a price per share equal to the lower of 135% of the daily VWAP prior to disbursement and 95% of the lowest VWAP during the three consecutive trading days immediately prior to the date on which Yorkville provides the purchase notice to Celularity, in each case subject to a floor price of 75c per share, and subject to certain share ownership limitations. Celularity could also be required to repay the pre-paid advance in certain circumstances by making monthly cash payments of $6M, plus any accrued and unpaid interest along with a 5.0% redemption premium until such time as the daily VWAP for five consecutive trading days immediately prior to the due date of the next monthly payment is at least 10% greater than 75c. Celularity intends to use the proceeds for working capital and other general corporate purposes. General corporate purposes may include research and development and clinical development costs to support the development of its cellular therapy candidates and the expansion of our research and development programs, as well as costs associated with its commercial biomaterials businesses; working capital; capital expenditures; and other general corporate purposes.

14:33 EDT Alaunos Therapeutics slides after 'patient two' referred to new trial - Shares of Alaunos Therapeutics are down $1.73, or 51%, to $1.67 in afternoon trading, which has been attributed by a Wall Street analyst to a blog post about a colon cancer patient with TP53 mutation who was involved in the company's clinical trial for an investigative TCR T-Cell immunotherapy for tumor based cancers. A relative of Danielle Woldt, who is identified as patient number two and "the first colon cancer patient in the study," stated in a post to the "GiveSendGo" crowdfunding site: "At some point during the past weeks Danielle started to feel better and have more energy. She even cooked a few meals for us, which she hasn't done in a long while. It appeared the Immunotherapy was having a positive effect, which was evidenced in the July CT Scan. You'll recall her primary tumor shrank 27% even though she'd been off chemo for several months to facilitate the trial. Then she started to feel bad again. Colon cancer is famous for adapting when pressured. It was under a lot of pressure, specifically the TP53 mutation the targeted therapy was engineered to seek out and kill... Septembers scan shows that the cancer has mutated. In my words it has gone "Willy nilly." It is not a good report. Inasmuch as the immunotherapy targeted the TP53 mutation specifically, which is now in the history books as it has mutated into something else, all those really cool T Cells are all dressed up with no place to go... We have been referred to the MD Anderson 'Early phase clinical trial team' who called a few minutes ago to set up an appointment. Danielle just filled out some electronic paperwork for a biopsy back in Houston as soon as it can be scheduled, probably in a couple weeks, which is when we'll meet with the new doctor who will be guiding the next step treatment(s). We anticipate probably starting with 'Lonsurf TAS-102 with Avastin' chemo to see if it buys us some time. Any new clinical trials will likely be in Houston at MD Anderson, the worlds leading cancer center." Cantor Fitzgerald analyst Prakhar Agrawal pointed to the blog post about the colon cancer patient in a note to investors, stating according to Bloomberg that he had believed "some optimism related to patient #2 was getting priced-in given the stock move in the last 1-2 weeks." Earlier this month, Alaunos Therapeutics announced early clinical findings from the TCR-T Library Phase 1/2 trial, an open label, dose escalation study being conducted at The University of Texas MD Anderson Cancer Center that is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers that have a matching human leukocyte antigen, or HLA, and hotspot mutation pairing in Alaunos' TCR library. "The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation, matching one of the ten TCRs within the Company's TCR library... The company has dosed a second patient in the study, diagnosed with colon cancer, who has been treated at the second dose level and has cleared the 28-day safety window. Data is scheduled to be presented during a proffered talk at CICON, which is being held in New York, NY from September 28 - October 1," the company stated.

13:46 EDT NetCapital notes crowdfunding quickly gaining popularity due to convenience - NetCapital (NCPL) allows private companies to raise capital online and provides private equity investment opportunities to investors. In an exclusive interview with The Fly, NetCapital Funding Portal CEO Jason Frishman talked about the space and the increasing popularity of fundraising platforms: "I think it's about control. Entrepreneurs love the idea of bringing their security offerings to people who are already the most passionate about their business as opposed to go to more traditional funding sources. It's kind of a new world since the pandemic because you can do so much behind your computer at your couch. Even though all these tools existed prior the pandemic, it was a little bit more difficult to get people to do sensitive transactions entirely online and then when the pandemic hit, we all became by necessity much more open and comfortable doing such. And tools like NetCapital were there to satisfied that demand. Companies still needed to raise capital and, in many cases, even more because of what was going on with COVID. Investors still had the demand to invest in innovation. Being able to look through quality deal flow and being able to get all the information at your fingertips and invest from the comfort of your couch, it's such a different and more efficient experience than the traditional way of doing things. I think it comes down to efficiency and convenience and control as you are able to bring your offering to the people you want. Also, marketing. It's a great marketing opportunity. It's not quite binary. If you invest time, effort and energy to get venture into your deal, you either get an investment or don't. But when you raise capital online, with a tool like NetCapital, you're doing a robust marketing campaign where there's a lot of room to succeed. Even if you don't end up raising the amount of capital you were looking, you still can earn hundreds or thousands of users just by the attention you're generating by doing that robust marketing campaign." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

13:30 EDT NetCapital's Frishman believes pandemic accelerated digital transition

13:30 EDT Funding Portal CEO says NetCapital is 'a facilitator, not a gatekeeper'

13:25 EDT Boeing CFO sees 'sufficient liquidity,' says investment grade rating 'important' - Asked at a conference how he thinks about rolling over debt or paying it down versus potentially raising equity, Boeing CFO Brian West replied: "So first of all, we believe we have sufficient liquidity combination of cash on hand and available revolver capacity, which is in the $12 billion range. So sufficient liquidity. I also -- I know that the investment-grade rating is important to us. It's a priority for sure. And then we have maturities that are coming at us, but manageable. There's $5 billion next year and there's $5 billion in 2024. As we think about our trajectory and our momentum, we believe that the natural underwriting of the business and the cash flows, driven by deliveries and execution, will satisfy those maturities. So that one feels fine. Our playbook on capital structure is very straightforward. We deliver airplanes. We generate cash flow. We invest in the organic priorities for the program development, and we pay down debt. It doesn't get any more complicated. We have to go execute, right? We have to execute in a world that is bumpy, but we got to execute. And we believe that as we've gone through this year, we've gotten sequential improvement, and we expect that sequential improvement to keep going. And we believe that over time, we'll get back to that point that you all know looks more normal."

13:16 EDT Boeing CFO 'confident' can remarket 737s intended for China - Asked during the Morgan Stanley Laguna Conference about 737 MAX returning to service in China, Boeing CFO Brian West replied: "So as we exited last year and got into February, both the customers in China and the regulators did exactly what they said they were going to do. And then February came -- and [end of] February, we actually had customers doing flight tests. And then everything stopped. And they paused because they had to deal with their COVID lockdown restrictions, et cetera. So right now, we are constantly communicating with our customers and the regulators, and we stand ready when that they're ready to pick up where they left off to finish that work, we are ready. I can't dictate the timing from we they take on. But I won't tell you more broadly, we have deferred decisions on those planes for a long time. We can't defer that decision forever. So we will begin to remarket some of those airplanes. They were otherwise earmarked for our Chinese customers. And we don't do that lightly. These customers are incredibly important. We're celebrating 50 years in China. It's an important market, but we've deferred this decision long and now we have to think about investors, where time to start to look to reposition. And the good news is we've got confidence and conviction that we can remarket them. So we got to navigate our way through that." Asked about the key obstacles for these airplanes to resume deliveries in China, West added: "They literally just have to get the regulator to say, you're ready to fly it again and return to service... We've just got to work through it when the regulator and the customer are ready, and we stand ready."

12:53 EDT Amazon.com launches Veeqo in U.S. - Amazon announced the U.S. launch of Veeqo, a multi-channel shipping software built to simplify fast-growth ecommerce. Acquired by Amazon earlier this year, Veeqo helps sellers cut shipping costs while increasing the speed of fulfilling customer orders. Sellers using Veeqo can connect their sales channels, including Amazon, eBay, Etsy, and Shopify, and access discounted rates on UPS, U.S. Postal Service, DHL, and FedEx. Veeqo's rate-shopping feature imports sellers' orders and automatically finds the lowest shipping rate available based on size and weight. "As a seller, I found that shipping orders and managing inventory across channels was time-consuming and error prone," Warren said. "The available shipping management software was complicated, lacked the right features, or was designed for an enterprise-sized retailer. I created a system built with the needs of all multi-channel sellers in mind. Sellers should be able to track, price, sell, and ship orders across multiple channels in just a few clicks, and with Veeqo they can." Previously priced at an average cost of $450 per month, Veeqo is now free for all sellers. Sellers who ship via Veeqo pay only for their chosen carrier labels, with no monthly fees.

12:00 EDT Steelcase falls -9.8% - Steelcase is down -9.8%, or -$1.06 to $9.71.

12:00 EDT Arconic falls -14.9% - Arconic is down -14.9%, or -$3.79 to $21.69.

12:00 EDT Delwinds Insurance Acquisition rises 22.3% - Delwinds Insurance Acquisition is up 22.3%, or $1.74 to $9.55.

11:56 EDT Air Canada to acquire 30 ES-30 electric regional aircraft from Heart Aerospace - Air Canada announced a purchase agreement for 30 ES-30 electric-hybrid aircraft under development by Heart Aerospace of Sweden. The revolutionary regional aircraft, expected to enter service in 2028, will generate zero emissions flying on battery power and yield significant operational savings and benefits. Under the agreement, Air Canada has also acquired a US$5 million equity stake in Heart Aerospace. "Air Canada has taken a leadership position in the industry to address climate change. The introduction into our fleet of the ES-30 electric regional aircraft from Heart Aerospace will be a step forward to our goal of net zero emissions by 2050," said Michael Rousseau, President and Chief Executive Officer of Air Canada. "Already, Air Canada is supporting the development of new technologies, such as sustainable aviation fuels and carbon capture, to address climate change. We are now reinforcing our commitment by investing in revolutionary electric aircraft technology, both as a customer for the ES-30 and as an equity partner in Heart Aerospace."

11:53 EDT PlayStation's 'Uncharted: Legacy of Thieves' arrives on PC October 19 - Sony's PlayStation unit announced that video game collection "Uncharted: Legacy of Thieves" arrives on PC October 19. The collection launched earlier this year on PlayStation 5 and includes two PlayStation 4 titles. The move marks the first time any game in the "Uncharted" franchise, which is owned by Sony, gets a PC port. Reference Link

11:33 EDT One Liberty Properties increases share repurchase authorization by $5.2M - OLP announced that the Board approved an approximate $5.2M increase to its existing share repurchase authorization. The expansion is in addition to the approximately $2.3M remaining on the current repurchase authorization, resulting in share repurchase authorization of up to $7.5M of common stock.

11:15 EDT Assa Abloy says 'will vigorously contest' DOJ effort to block deal with Spectrum - After the U.S. Department of Justice announced that it will seek to block Assa Abloy's (ASAZY) proposed acquisition of the HHI division of Spectrum Brands (SPB), Assa Abloy and Spectrum Brands said they "strongly disagree with the Department of Justice's characterization of the proposed transaction, and will vigorously contest in court this effort by the DOJ to oppose the transaction." Nico Delvaux, President and CEO of Assa Abloy, stated: "We believe strongly in the acquisition of HHI as we together will increase investments in the residential segments and strengthen our combined product offering for the benefit of consumers." Assa Abloy and Spectrum Brands are "committed to completing the transaction and are confident that they will prevail in litigation," the company added. Reference Link

10:59 EDT Norfolk Southern says moving immediately to restore service with strike averted - Norfolk Southern issued a service update that states in part: "Early this morning, the nation's rail carriers reached agreements with all of the industry's labor unions to avert a potential strike ahead of Friday's deadline. We are moving immediately to resume normal operations and restore service that had been curtailed in anticipation of a potential strike. Thank you for your patience and support through this challenging process. Many of you voiced your support for agreements based on the recommendations of President Joe Biden's Presidential Emergency Board. Your efforts played an important role building momentum for the voluntary agreements... Although the immediate threat of a service disruption is behind us for now, we understand that our service is still not at the level you expect. Building on our recent improvements in service remains the top priority of our entire organization."

10:37 EDT Align Technology opens EMEA regional manufacturing facility in Poland - Align Technology announced the official opening of the first Europe, Middle East & Africa regional manufacturing facility in Wroclaw, Poland. The new plant is Align's third regional manufacturing facility worldwide, after Juarez, Mexico and Ziyang, China. The facility in Wroclaw, Poland, will serve as an operations site for Align's EMEA business and be part of the global manufacturing of almost 1 million unique clear aligner parts per day. The new Align manufacturing facility is expected to add more than 2,500 jobs by the end of 2025, making it the company's largest investment in the region to date. The new building has an 80,000m2 surface and follows Align sustainability norms, including LEED and ISO14001 certificates.

10:35 EDT Spectrum Brands vows to 'vigorously oppose' DOJ suit on unit sale - Spectrum Brands (SPB) announced that it will "vigorously oppose" the Department of Justice's attempt to block the company's sale of its Hardware and Home Improvement business to Assa Abloy (ASAZY). Spectrum Brands and Assa "are committed to completing the transaction and are confident that they will prevail in litigation." On September 8, 2021, Spectrum Brands announced that it had signed an agreement to sell its HHI business to Assa for $4.3B in cash. Spectrum said in a statement, "The DOJ's lawsuit challenging the transaction ignores the realities of this dynamic industry and the highly competitive landscape of the residential security marketplace, in which there are many capable and vigorous competitors and rapid, easy entry by new firms. This transaction will only further increase HHI's ability to deliver the innovations consumers demand. The combined entity will deliver more value and innovation to customers and enhance competition overall in an ever-changing marketplace." David Maura, the company's Chief Executive Officer, said, "Despite disagreeing strongly with the DOJ's purported concerns, in the spirit of compromise - and to speed delivery of the concrete benefits this transaction offers all stakeholders - Spectrum Brands and ASSA ABLOY made numerous proposals to address the DOJ's concerns, each of which were rejected without a valid basis. Their choice to pursue litigation places political ideology above the interests of American consumers and workers. We are confident that the Court will agree with us and will allow us to close the transaction."

10:25 EDT Adobe expects Figma transaction to be accretive at end of year three - Adobe says Figma transaction expected to be accretive to Adobe Non-GAAP EPS at the end of year three. Adobe to maintain share repurchases sufficient to offset dilution of equity issuances to Adobe employees while the transaction is pending. Comments taken from Adobe's earnings conference call.

10:16 EDT Spectrum Brands trading halted, volatility trading pause

10:12 EDT Teamsters say tentative rail agreement to improve conditions, safeguard wages - The International Brotherhood of Teamsters said it "applauds the tens of thousands of members of the Teamsters Rail Conference for working long into the night to reach a tentative agreement averting a potential railway strike." The union stated: "The tentative agreement will improve working conditions and safeguard wages and health care benefits for the 57,000 members of the Teamsters Rail Conference. In addition to wage increases and bonuses, new contract language was negotiated exempting time off for certain medical events. The agreement includes provisions to create voluntary assigned days off for members, and all members will receive one additional paid day off. Most importantly, Teamsters will have the ability to take time away from work for routine and preventive medical care, as well as exemptions from attendance policies for hospitalizations and surgery." Publicly traded companies in the rail space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP). Reference Link

10:07 EDT Spectrum Brands extends selloff, shares down 9% to $53.57

10:05 EDT Spectrum Brands drops 6% to $55.10 after Bloomberg report on unit sale

10:02 EDT LPL Financial, Kaplan enter strategic educational agreement - Kaplan has announced a strategic educational agreement with LPL Financial.As a new participant in LPLs Vendor Affinity Program, Kaplan will provide a comprehensive portfolio of financial education offerings with enhanced discounts to advance the training and skills of LPL Financials employees, independent financial advisors, and those employed at its affiliate banks and lending institutions. This expands Kaplans long-standing partnership with LPL to provide products and services to LPL advisors.

10:00 EDT CVR Energy falls -8.1% - CVR Energy is down -8.1%, or -$2.65 to $30.09.

10:00 EDT Freyr Battery rises 8.3% - Freyr Battery is up 8.3%, or $1.12 to $14.69.

10:00 EDT AMTD Digital rises 82.7% - AMTD Digital is up 82.7%, or $156.73 to $346.15.

09:56 EDT Snap says Snapchat for Web now available to all - Snap said in a blog post: "This Fall, we're introducing new features to help keep conversations with friends fresh, fast, and easy to find! Our new Lock Screen Widgets, available now with iOS 16, keeps conversations with your bestie saved right to your lock screen so you can start chats with one tap... Widgets aren't the only thing customizing your screen this Fall: New Chat Shortcuts at the top of our chat tab will make it easy to do things like spot unread Snaps and Chats from friends, see missed calls, and reply to stories... We are also introducing new tools like Question Stickers so you can AMA-all-day from your Snapchat Story, plus (and just in time for back to school) we're making Snapchat for Web available to all!" Reference Link

09:47 EDT United States Natural Gas Fund falls -6.4% - United States Natural Gas Fund is down -6.4%, or -$2.02 to $29.43.

09:47 EDT Arconic falls -6.9% - Arconic is down -6.9%, or -$1.76 to $23.72.

09:47 EDT Store Capital rises 20.5% - Store Capital is up 20.5%, or $5.49 to $32.28.

09:41 EDT A2Z Smart Technologies announces Smart Carts availability at Chedraui - A2Z Smart Technologies announced that twelve of the Company's smart cart solution will be available to the public at Chedraui's flagship store in Mexico City after the completion of a successful integration process with Toshiba point-of-sale and extensive internal testing by Chedraui.

09:37 EDT Terumo Cardiovascular opens manufacting facility in Costa Rica - Terumo Cardiovascular marked the opening of its newest manufacturing plant in La Lima, Cartago, Costa Rica. The new facility is home to Terumo's Perfusion Circuit Technology and Manufacturing Center and welcomes the first company to produce this line of medical equipment in Costa Rica. The Company's $42M investment in its global manufacturing operations supports its mission of Contributing to Society through Healthcare and saving lives.The company's modern facility is 157,000 square feet and leverages state-of-the-art systems and a highly trained workforce. Costa Rica operations launched on August 3 and will primarily serve customers in the Americas and Australia. A second phase which launches in early 2023 will supply customers in Europe, the Middle East, and Africa. Local operations are expected to employ about 300 associates by the end of 2022.

09:36 EDT AMTD Digital Inc - ADR trading resumes

09:35 EDT Creatd partners with Equinox to showcase Dune - Creatd has partnered with luxury health club chain Equinox to introduce their fitness club members to Dune, Creatd Ventures' wellness beverage brand. At an initial event early this week, fitness club members were introduced to samplings of Dune beverages and gifted a selection of Dune branded products. As part of the collaboration, Dune is offering all Equinox club members exclusive promotions to subscribe to Dune.

09:31 EDT AMTD Digital Inc - ADR trading halted, volatility trading pause

09:25 EDT Cosmos Holdings to launch Sky Premium Life products in Germany, Austria - Cosmos Holdings announced that the Company's proprietary line of nutraceuticals, Sky Premium Life, has entered into an exclusive agreement with Mediprovita GbR. Mediprovita will begin selling its Sky Premium Life products in Germany and Austria beginning in the Fourth Quarter. The initial order for 20 SKUs will be sold through Amazon, Ebay, and Mediprovita's own ecommerce website. The Company expects to extend its relationship with Mediprovita in the near future to include the distribution of 70 SKU's.

09:23 EDT Omeros falls 6% after results from narsoplimab arm of I-SPY COVID Trial - Omeros is down 6% or 32c per share to $5.07 per share in pre-market trading.

09:22 EDT U.S. Steel slips after Q3 earnings guidance - Shares of U.S. Steel are down 0.6% in pre-market trading at $20.30 after the company guided its Q3 earnings in $1.90-$1.95 range vs. consensus $1.90 but also updated its Q3 EBITDA outlook to $825M vs. prior forecast of "just under $1B". In its Q3 EBITDA commentary, the company stated: "The Flat-rolled segment's adjusted EBITDA is expected to be lower than the second quarter. Accelerating market headwinds in the third quarter negatively impacted demand across most end-markets, which is expected to result in lower shipment volumes. Supply chain issues in automotive and appliance end-markets continue, while containers and packaging has softened, and service center buyers remain on the sidelines. Fixed price contracts in our Flat-rolled segment are expected to limit the negative impact to the segment's average selling price from the flow-through of lower steel selling prices in spot business and monthly contracts. The Mini Mill segment's adjusted EBITDA is expected to be significantly lower than the second quarter's strong performance. Weaker demand and significantly reduced average selling prices from the segment's exposure to spot selling prices are expected to negatively impact the segment's EBITDA performance. In addition, high-cost raw materials procured at the onset of the war in Ukraine began to impact margins in the third quarter and are expected to impact results through year-end. The European segment's adjusted EBITDA is also expected to be significantly lower than the second quarter. Demand challenges have accelerated through the third quarter due to seasonal buying patterns and the increasing effects of the war in Ukraine which has fueled macroeconomic uncertainty and rising energy costs. Lower steel prices are increasingly being reflected in the segment's majority spot mix exposure. Additionally, headwinds from high-cost raw materials procured at the onset of the war in Ukraine, an extended supply chain and surging energy costs are causing significant margin pressure. These challenges informed our decision to pull forward a planned blast furnace outage from October into September to better balance supply with softer demand. The Tubular segment's adjusted EBITDA is expected to improve on last quarter's strong performance. Continued healthy demand and the trade case on oil country tubular goods imports is resulting in higher selling prices and higher expected EBITDA compared to the second quarter. The segment continues to be advantaged by its electric arc furnace supplying internally sourced rounds substrate and the margin expansion from the segment's proprietary connections."

09:20 EDT Avicanna announces new collaboration with University of Toronto - Avicanna announces that it has expanded its research collaboration in field of Epilepsy with a new collaboration with the University of Toronto and Dr. Mac Burnham's research team to explore the efficacy of Avicanna's proprietary formulations in pre-clinical models for Epilepsy. New research collaboration with University of Toronto: The research collaboration led by Dr. Mac Burnham's team will explore the efficacy of Avicanna's drug candidates including AVCN319302 in animal models for Epilepsy. In addition, the research collaboration will evaluate the anti-seizure properties of rare cannabinoids in isolation and in combination. Ongoing research collaboration with University Health Network: The research by Dr. Burnham's team will expand on an existing collaboration with the University Health Network and Dr. Peter Carlen, a professor of medicine and physiology at Temerty Faculty of Medicine, and senior scientist at the Toronto Western Research Institute.

09:18 EDT Caladrius, Cend close merger, become Lisata Therapeutics - Caladrius Biosciences and Cend Therapeutics announced that the proposed merger of the two companies has closed following the approval of Caladrius' stockholders on September 13, 2022. The merged company will operate as Lisata Therapeutics and will focus primarily on advancing its CendR Platform technology product candidates in a range of oncology indications, in addition to Caladrius' existing development programs. Lisata will commence trading on The Nasdaq Capital Market today, September 15, 2022, under the ticker symbol "LSTA". Following the closing of the merger, David J. Mazzo, Ph.D., current President and CEO of Caladrius will continue as the CEO of Lisata, David Slack, MBA, current President and CEO of Cend, will be Lisata's President and CVO, and Kristen K. Buck, M.D., current Executive Vice President of R&D and CMO of Caladrius, will continue in those roles with Lisata. Lisata's cash and investments, as of immediately following the closing of the merger, are approximately $76 million. Prior to the closing of the merger, Caladrius effected a 1-for-15 reverse split of its common stock. Post-merger and post-reverse split, Lisata has approximately 7.8 million shares of common stock issued and outstanding, with prior Caladrius stockholders collectively owning approximately 52% of the combined company and prior Cend stockholders collectively owning approximately 48% of the combined company.

09:16 EDT Neovasc comments on new ICD-10-CM Diagnosis Codes for refractory angina - Neovasc commented on the Centers for Medicare and Medicaid Services, CMS, development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th revision of the International Statistical Classification of Diseases and Related Health Problems Clinical Modification. The latest update was published in the ICD-10-CM Tabular List of Diseases and Injuries 2023 Addenda and will be effective October 1, 2022. In total, nine new refractory angina codes were created. "Today's announcement is another important step forward for patients with refractory angina and for the Neovasc Reducer as an option for treating this disease," added Bill Little, Neovasc Chief Operating Officer. "The creation of the new ICD-10-CM codes will help to ensure appropriate measurement of the costs and clinical outcomes in patients who suffer from the burden of refractory angina."

09:14 EDT Omeros reports results from narsoplimab arm of I-SPY COVID Trial - Omeros reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative, or QLHC. Analysis in the randomized patient population shows that the addition of narsoplimab to treatment of critically ill patients with COVID-19 reduces the mortality risk. Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. There were 91 patients randomized to the narsoplimab arm of the trial across 27 participating U.S. sites. The 91 randomized patients were compared to the 116 patients concurrently randomized to the control arm. All patients received standard of care including dexamethasone and remdesivir. Bayesian statistics were prespecified and employed for analyses. Narsoplimab was to be administered at a dose of 4 mg/kg given as a 30-minute intravenous infusion twice weekly for the earlier of a total of 4 weeks or until hospital discharge. However, in approximately half of the patients who died in the narsoplimab group, narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Despite narsoplimab treatment exposure in a limited number of patients in this trial, a substantial efficacy signal was observed in reducing the risk of mortality for critically ill COVID-19 patients. Narsoplimab was not observed to shorten the time to recovery in critically ill patients with COVID-19 in this study. The study did not identify any new safety signals for narsoplimab in the setting of critically ill COVID-19 patients. The I-SPY COVID Trial was designed for rapid screening of agents that show promise for two primary endpoints in critically ill COVID-19 patients: the time to recovery and the risk of mortality. The study utilizes QLHC's adaptive platform trial design methodology, which focuses on the simultaneous, efficient assessment of multiple investigational agents. To streamline enrollment and allow rapid assessment of multiple drugs as required during the pandemic, the platform trial's initial design included a requirement that patients be randomized prior to consenting to trial participation. While the motivation for this sequence and the analysis of the consented population is outlined in The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations, such analyses have risk of bias. To protect against potential bias associated with analysis only in the consented population, QLHC also prespecified analyses based on all randomized patients. Substantial imbalance in the consented population was detected and created a marked and statistically significant bias against the narsoplimab arm, rendering analysis of the consented population meaningless. However, as pre-specified by the analysis plan, the I-SPY trial's data monitoring committee terminated the narsoplimab arm based on the biased analyses in the consented population prior to reaching the maximum of 125 patients. Neither the trial's futility nor graduation criteria had been met in the analysis of the randomized population at the time the narsoplimab arm was terminated. Avoiding similarly biased outcomes in future trial arms, QLHC subsequently revised the protocol for its I-SPY COVID Trial to obtain patient consent prior to randomization.

09:12 EDT AMMO to host ribbon cutting ceremony for opening of Manitowoc, WI - AMMO announces it will host a ribbon cutting ceremony at its new 185,000 square foot state-of-the-art production facility. The ceremony is open to the public.

09:12 EDT Iveco Group announces creation of Green & Advanced Transport Ecosystem - Iveco Group announces the creation of a new entity, GATE - Green & Advanced Transport Ecosystem, a long-term, all-inclusive rental model for electric trucks and vans, which will powerfully support the industry's energy transition. The expected operational launch date is mid-2023, when GATE, as a fully digitalised business, will begin offering its services to pilot clients in Italy. GATE is going to have an independent business structure with employees dedicated to meeting the needs of electric commercial vehicle customers, initially serving both the IVECO and Nikola brands. The new entity will offer a comprehensive service based on a pay-per-use formula that will allow customers access to the propulsion of tomorrow. A full ecosystem focused on a variety of zero-emission vehicles, from last mile delivery to long haulage. With green equipment at its core, the ecosystem will deliver sustainable solutions to customers, who can define the level of support and flexibility they require to run their business and make the most of all the services GATE will make available, including maintenance & repair, connectivity and telematics, financing, insurance, energy, and additional ancillary services.

09:10 EDT Positive Physicians Insurance, Medical Interactive enter partnership - Positive Physicians Insurance Company and Medical Interactive Community announced a partnership to provide Positive insured physicians and healthcare providers access to MI's e-learning platform. This e-learning platform will equip Positive's insureds with a comprehensive library of educational and training resources that target key areas of clinical risk, as well as the ability to earn CME, CNE, and MOC-approved credits at no additional cost. The platform also allows insureds to automatically report completed credits to appropriate state boards via CE Broker.

09:08 EDT Senmiao Technology signs ride platform agreement with SOE in Chengdu - Senmiao Technology's wholly owned subsidiary Chengdu Xixingtianxia, or XXTX, has signed an agreement with Chengdu Rongcheng Yueda, an affiliate of Chengdu City Construction Investment, a state-owned enterprise in Chengdu with RMB160B in assets. Yueda will utilize Senmiao's online ride-hailing platform to provide ride-hailing services by appointment in Chengdu, using its own vehicle and driver resources. Yueda will be responsible for the management services of its own drivers. Senmiao will assign online ride orders to Yueda's drivers and provide real-time information including service types and prices. The partnership commenced in August 2022 for a term through July 31, 2023, subject to agreement renewal or early termination.

09:08 EDT Philips highlights FetView cloud-based image sharing, reporting software - Royal Philips announced the upcoming addition of the FetView cloud-based fetal ultrasound image sharing and reporting software for obstetrics/gynecology. As a vendor-neutral cloud-based platform for ultrasound images, FetView will utilize the ultrasound image data to convey fetal growth projections and provide a user-friendly platform for physician to physician and physician to patient communication. Philips Fetview is an integrated solution that combines fetal ultrasound imaging with enhanced reporting and easy access to an expectant mother's medical data and fetal images. All results are securely stored and displayed in real time. With this upcoming addition of FetView into Philips' advanced portfolio for Ultrasound in OB/GYN - which includes Lumify Handheld Ultrasound, diagnostic ultrasound systems EPIQ, Affiniti and mobile app Pregnancy+ - pregnant women and their care teams will have access to a comprehensive overview of how a pregnancy is progressing to help provide peace of mind to patients and enhance diagnostic confidence for clinicians. With OB/GYN ultrasounds performed in different clinical settings, immediate remote access to ultrasound images and medical histories for collaborative decision-making and easy sharing of images with patients is a challenge. Philips FetView will allow physicians to view, analyze, and annotate ultrasound images in real time via a cloud-based browser-accessible platform for secure image sharing, to help improve quality access to care, reduce patient mobility in case of high-risk pregnancies or post-surgery conditions, and reduce the need to rescan patients. By enabling full digitalization of OB/GYN workflows and patient management, Philips FetView will help drive greater departmental efficiency, reduce costs, and provide a better patient and staff experience.

09:07 EDT Verisk launches Profitability Advisor on MarketStance Commercial Insight - Verisk has launched Profitability Advisor on the MarketStance Commercial Insight platform, further enhancing an already powerful commercial lines market analysis tool.

09:06 EDT SunPower makes minority investments in EmPower Solar, Renova Energy - SunPower (NASDAQ:SPWR) announced it has made minority investments in EmPower Solar and Renova Energy. With these investments, Renova and EmPower are the newest additions to SunPower's Dealer Accelerator Program. The Dealer Accelerator Program, which SunPower launched in March, provides high-potential solar dealers with capital financing and business strategy support to accelerate growth and meet the increasing homeowner demand for solar nationwide. Dealers in the program exclusively sell industry leading SunPower solar systems. They also offer SunVault battery storage and leverage SunPower Financial offerings for solar financing.

09:05 EDT Bloomin' Brands and Just Eat Takeaway.com-s Grubhub expand partnership - Bloomin' Brands (BLMN) and Just Eat Takeaway.com's (TKWY) Grubhub are expanding their partnership to bring all of Bloomin' Brands concepts to the Grubhub Marketplace. All Bloomin' Brands concepts will be available on Grubhub for pickup or delivery, adding to the select Carrabba's Italian Grill locations already available on the platform. More than 1,700 listings will be available across the country, including more than 1,000 restaurant locations and 700 virtual kitchens. Several offers are now available for new and existing diners exclusively through Grubhub for a limited time.

09:04 EDT Sorrento announces completion of first Phase 1b study using Sofusa - Sorrento Therapeutics announced completion of its first Phase 1b proof of concept study using the Sofusa Lymphatic Drug Delivery System, Sofusa. STI-SOFUSA-1003 is a Phase 1b proof of concept study designed to evaluate safety, and also test the hypothesis that Sofusa's unique biodistribution profile could improve clinical response, reduce the amount of drug required to achieve a response, or both. To be eligible for the study, participants had to be on a stable dose of 50mg of etanercept and not responding adequately to the etanercept subcutaneous treatment. Preliminary results indicate that 100% of the patients who have completed the first cohort of the study achieved a significant improvement in their Rheumatoid Arthritis Disease Activity at 50% of the subcutaneous dose. The ACR Abstract Selection Committee has accepted an abstract entitled "Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections."

09:04 EDT Smart Communications announces expanded integration with Duck Creek - Smart Communications announced expanded integration with leading insurance platform, Duck Creek. As customer preferences continue to shift digitally, these added connectors will support insurance companies looking to service their policyholders with personalized, interactive conversations and digital experiences at scale.

09:02 EDT Edwards Lifesciences' PASCAL Precision system receives FDA approval - Edwards Lifesciences announced the company's PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair has received FDA approval for the treatment of patients with degenerative mitral regurgitation. The commercial opportunity related to this approval is factored into 2022 financial expectations.

09:01 EDT Meta Platforms' Instagram to allow payments capability within its messages - Yesterday afternoon, the company stated: "Each week, one billion people message a business across our apps-whether it's chatting with brands, browsing products, asking for support or interacting with Instagram Reels. We want to help people start conversations with businesses they care about and help them find and buy products they love in an easy, seamless experience. That's why we're introducing a new way to make a purchase on Instagram-right where you chat with your customers. Now your business can accept payments in your Direct Messages. That means your customers can pay you without switching apps, giving them a more personalized and convenient shopping experience that can help drive sales and grow your business. There are no fees to accept payments in chat, and you'll have access to 24/7 customer support if you need help." Reference Link

08:54 EDT PCTEL receives FCC regulatory certification for new industrial IoT Radio Module - PCTEL announced receipt of certification from the Federal Communications Commission for its Industrial IoT Radio Module. PCTEL's Industrial IoT Radio Module, RM-WIFI-AC-2X2-HP, meets rigorous requirements for Industrial IoT applications, helping users in increasing operational efficiency with reliable connectivity. This rugged, high power 802.11ac WiFi radio module supports 5 GHz WiFi bands and can be installed in a wide variety of products that accept standard mini-PCIe cards. Purpose-built to support industrial applications targeting a range of end markets including utilities, fleets, manufacturing, automation, mining, and oil and gas, this module's small form factor makes it ideal for integration into wireless IT platforms. Its high transmit power provides reliable connectivity.

08:45 EDT Jupiter Wellness issues shareholder letter, corporate update - Jupiter Wellness published a shareholder letter and company update detailing recent progress and their renewed focus on science-backed product development. "We have had a great start to the year. We're coming off a record quarter for revenue and hitting several key milestones for our company," said Brian John, CEO of Jupiter Wellness. "We are executing a pivot back to our roots and putting a renewed focus on the science that founded this company. We spent the last year developing, patent protecting, and clinically testing our core products. We expanded our CRO business with the acquisitions of Applied Biology. We signed several agreements to license our products, including Taisho a $2.6 billion revenue company and Japan's leading seller of minoxidil products. Lastly, we are turning our focus now to the development and launch of our eczema and sexual wellness products."

08:44 EDT Blue Apron enters carbon management partnership with Planet FWD - Blue Apron announced a partnership with Planet FWD, the carbon management platform for consumer companies, as it continues to take actionable steps towards its goal of net zero. Through this partnership, Blue Apron plans to conduct a more thorough review of its Scope 3 emissions by leveraging Planet FWD's platform to measure, report and plan action on its carbon footprint for its meal kits as well as company-wide emissions. Blue Apron is the first meal-kit on the platform.

08:42 EDT Steel Dynamics jumps 5% to $78.26 after Q3 EPS guidance beats estimates

08:41 EDT Lifeist's Mikra Cellular increases active monthly subscriber count by 137% in Q3 - Lifeist Wellness announced that its U.S. biosciences subsidiary Mikra Cellular Sciences has increased its active monthly subscriber count by 173% in Q3 2022 compared to Q2 2022 for CELLF, its first product which combats brain fog and unlocks healthy aging at a cellular level. This level of compounding growth highlights Mikra's ambition to carve out a significant segment of the emerging cellular health category. Launching during Q4 2022, CELLF v1.2 is the latest in Mikra's innovation across its flagship line CELLF, the modern multivitamin for your cellular health. CELLF v1.2 advances three key objectives for Mikra: Expand Distribution. There has been significant inbound demand for CELLF from small, medium, and large chain wholesalers. This newest version of CELLF reduces the size of packaging adhering to best "on shelf" practices while also reducing shipping and logistic costs, such as storage. These improvements are expected to facilitate CELLF's future growing distribution on online marketplaces and bricks and mortar stores. Improve Customer Lifetime Value. Improvement in taste, package dispensing, and environmental consideration have all been addressed in CELLF v1.2. In this newest version, CELLF's sachet system is fully recyclable and utilizes an "easy to dispense" technology so that a consumer can easily consume CELLF with one hand. Without effecting the delivery mechanism or adding any sugars, the Mikra team has dramatically improved the taste of CELLF which has been one of the key components of customer churn. Improve Profitability and Growth. Margins and distribution have been a key focus for Mikra, and with CELLF v1.2, product gross margins are expected to grow to over 65% primarily driven by increased order volume, as well as formulation and supply chain efficiencies. This incremental improvement on CELLF is opening more distribution opportunities within Q4 2022. As Mikra's brand footprint grows, it enjoys increased engagement across all social channels and numerous earned media opportunities. Olympic Champion Cullen Jones has deepened his partnership with Mikra by beginning an in-depth partnership with Gear Patrol, a daily magazine for men that covers everything in gear, travel, adventure, design, food, and culture. The partnership, which is expected to launch within Q4 2022, focuses on how CELLF has impacted Jones' performance and life.

08:38 EDT Coherent introduces 200G indium phosphide EMLs for datacenter transceivers - Coherent announced the introduction of its 200 Gbps indium phosphide electro-absorption modulated lasers for high-speed datacenter transceivers

08:38 EDT HeartBeam gets patent for 12-lead ECG patch monitor for cardiac care - HeartBeam announced that its patent for a 12-lead electrocardiogram ECG patch monitor intended for detection of acute coronary syndrome ACS and cardiac arrhythmia was issued by the United States Patent and Trademark Office. The innovation builds on HeartBeam's growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting. The global ECG patch monitor market, estimated to reach $4.8B by 2030, is currently limited to arrhythmia detection via the use of single-lead ECG devices. By elevating patch monitor technology with a synthesized 12-lead ECG, HeartBeam can aid physicians in both arrhythmia detection and ACS diagnosis including myocardial infarction and angina.

08:36 EDT Surgalign announces third clinical site in commercialization of HOLO Portal - Surgalign announced further advancement in the commercialization of its HOLO Portal surgical guidance system. The Company reports that Jaideep Chunduri, MD, a board certified orthopaedic and spinal surgeon at Beacon Orthopedics & Sports Medicine in Cincinnati, Ohio, performed his first case with the HOLO Portal surgical guidance system. HOLO Portal, the world's first surgical guidance system to incorporate AI and AR, represents the initial clinical application of Surgalign's HOLO AI digital health platform. "Congratulations to Dr. Chunduri for completing his first surgical case with the SurgalignTM HOLO Portal system," said Terry Rich, President and CEO of Surgalign. "The performance to date of the HOLO Portal system and the surgeon excitement generated by the technology have validated our high expectations. We believe that our HOLO AI technology will transform patient outcomes, and we couldn't be prouder to partner with Dr. Chunduri."

08:35 EDT Sypris Solutions acquires intellectual property rights for ROC line - Sypris Technologies, a subsidiary of Sypris Solutions, announced that it has recently acquired the intellectual property rights for the rapid opening closure, or ROC, product line from Pipeline Engineering and Supply Co. Limited, located in Catterick, UK. The terms and conditions of the transaction were not disclosed. The purchase of the intellectual property provides Sypris with the exclusive right to use the purchased IP to manufacture and sell the ROC product line to end users globally, including those in the oil, gas, petrochemical and industrial markets. Under the agreement, Sypris will also have the capability to supply spare parts and provide field service for any installation that contains the ROC product line. The transaction combines certain of the flow assurance products of PE, with over 50 years of installed base, with the Tube Turns brand of products from Sypris, which has been manufacturing and selling highly engineered competing products for use in strategic oil, gas and petrochemical infrastructure projects around the world for over 60 years.

08:35 EDT NeuroBo Pharmaceuticals and Dong-A ST partner for cardio-metabolic therapies - NeuroBo Pharmaceuticals and Dong-A ST have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis or NASH, obesity and type 2 diabetes. Under the license agreement, NeuroBo will be responsible for global development, regulatory and commercial activities other than for certain Asian-Pacific geographies. Dong-A will manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Korea. Dong-A will receive an upfront payment of $22M in Series A convertible preferred stock, which will automatically convert into common stock upon receipt of requisite stockholder approval, and will be eligible to receive commercial- and regulatory-based milestone payments, dependent upon the achievement of specific regulatory and commercial developments. Dong-A will also be entitled to single digit royalties on net sales of the two assets. Dong-A has also agreed to commit $15M toward financing the assets, subject to NeuroBo's ability to obtain additional financing under the terms of the license agreement. The transaction is expected to close in Q3, subject to obtaining third party financing for development of the assets and other customary closing conditions.

08:35 EDT Marqeta announces $100M share repurchase program - Marqeta announced that its Board of Directors has unanimously authorized a share repurchase program of up to $100M million of Marqeta's Class A common stock. "The share repurchase program demonstrates the confidence Board and management team have in the strength of our business and future growth prospects," said Jason Gardner, Founder and CEO of Marqeta. "We see a specific moment-in-time opportunity for us to execute a share buy-back program as we do not believe our current valuation reflects our performance or our long-term market opportunity. Our strong balance sheet with $1.7 billion in liquidity enables us to execute this program while continuing to invest in both organic and inorganic opportunities to grow the business."

08:33 EDT Celsion completes enrollment of Phase I/II OVATION 2 study - Celsion announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company's IL-12 gene-mediated immunotherapy. Topline results are expected in the second half of 2023. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy, NACT, in patients newly diagnosed with Stage III/IV ovarian cancer. NACT is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. "We are delighted to reach this important milestone of completing enrollment in our Phase I/II OVATION 2 Study with GEN-1 and are optimistic the study will show our technology's ability to deliver the powerful immune-modulating agent IL-12," said Corinne Le Goff, Ph.D., president and chief executive officer of Celsion Corporation. "Preliminary interim data in this study are very promising, showing both safety and activity. We look forward to completing the study and reporting top line results, in the second half of 2023."

08:32 EDT Shuttle Pharmaceuticals awarded new HDAC inhibitor patents for cancer treatment - Shuttle Pharmaceuticals has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing side effects and improving outcomes for cancer patients treated with radiation therapy. Treatment with HDAC inhibitors allows regulation of gene expression by blocking HDAC enzyme activity and allowing genes to be "turned on" to express proteins involved in regulation of the cell cycle, DNA damage response and immune activation. Inhibiting HDAC enzymes can turn on tumor suppressor genes to help control cell division and slow down cancer progression. The company's HDAC inhibitor technology platform has European applications under review.

08:29 EDT Telos enters collaboration with IBM Security - Telos Corporation (TLS) announces a collaboration with IBM Security (IBM) as part of IBM's Active Governance Services that allows enterprises to operationalize and automate activities and solve challenges in cybersecurity compliance and regulatory risks.

08:25 EDT Tenax Therapeutics trading halted, news pending

08:23 EDT Zentek says Phase 1 testing under ISC Testing Stream contract meets all targets - Zentek reports that it has received the final report from Phase 1 testing under its Innovation Solutions Canada Testing Stream contract, which notes that all Phase 1 targets were met including: a sufficient reduction in live airborne test organisms without modification to existing HVAC systems, no reduction in air flow rates, and no significant shedding of the ZenGUARD coating. ZenGUARD-coated HVAC filters demonstrated a maximum improvement of 99% compared to equivalent MERV-rated uncoated filters using a bacteriophage. Phase 1 testing was conducted by CremCo Laboratories with assistance by the Aerospace Research Centre, a department of the National Research Council of Canada. Zentek is now in Phase 2 Testing at the National Research Council to demonstrate a reduction in live airborne surrogate contamination within a modular classroom environment, simulating a real-world environment. The Company will report results when completed and validated.

08:18 EDT Cardinal Energy announces inclusion in 2022 TSX30 - Cardinal Energy is proud to announce that we have been included in the Toronto Stock Exchange's 2022 TSX30, a flagship program recognizing the 30 top performing TSX stocks over a three-year period based on dividend-adjusted share price appreciation. For the three years ended June 30, 2022, Cardinal's share price increased by 222%.

08:16 EDT Merrion Investment opposes sale of Avalara to Vista Equity Partners - Merrion Investment Management Company, an SEC-Registered Investment Advisor that is a long-term owner of Avalara, announced its opposition to the purchase of Avalara by Vista Equity Partners. MIMCo issued the following statement: "Avalara, Inc. announced on August 8, 2022 that it had agreed to be acquired by Vista Equity Partners at a price of $93.50/share in cash. Merrion Investment Management clients have been investors in AVLR common shares since October 2019. Since then, AVLR has achieved extraordinary growth and has posted remarkable metrics among its software-as-a-service peer group, most notably in client retention and acquisition costs. In addition, AVLR has managed its capital base in a manner that prepared the company well for the difficult market period now upon us. A well-timed convertible bond offering and rapidly improving operating efficiency bring AVLR into late 2022 with ample liquidity. AVLR is perfectly capable of remaining independent and has many years of profitable growth ahead. In light of this, the Board of Directors' decision to conduct an auction at this time in a depressed and volatile macroeconomic market seems ill-advised. The price agreed appears completely devoid of any control premium appropriate in this situation. We intend to vote against the Vista transaction."

08:15 EDT Lavoro to become public through TPB Acquisition I combination - TPB Acquisition I (TPBA), a special purpose acquisition company sponsored by The Production Board, and Lavoro, an agricultural inputs retailer in Latin America, announced that they have entered into a definitive business combination agreement that will result in Lavoro becoming a U.S. publicly listed company. The transaction is expected to close in the fourth quarter of 2022, subject to the satisfaction of customary closing conditions, a new U.S. publicly-listed entity is expected to be listed on the Nasdaq under the ticker symbol (LVRO). Upon listing, Lavoro will become the first U.S.-listed pure-play Latin American agricultural inputs retailer. Following the proposed business combination with TPB Acquisition Corp., Lavoro expects to increase market share through retail expansion, continued operational improvements, and additional acquisitions. The proposed business combination values Lavoro, following the business combination, at an implied initial enterprise value of approximately $1.2B. The transaction is expected to result in up to $225M in net cash proceeds to Lavoro after closing, including the contribution of up to $180M from the cash held in the trust account of TPB Acquisition Corp. and $100M that TPB intends to invest through a private placement at $10.00 per share; $30M in secondary proceeds to investment funds managed by Patria Group, the controlling shareholders of Lavoro, and $25M in expected transaction fees and expenses. The implied enterprise value equals 7.1x pro forma adjusted EBITDA for Lavoro in calendar year 2022 and 4.4x pro forma adjusted EBITDA for calendar year 2023. At the closing of the proposed business combination, TPB will vest two-thirds of its sponsor promote shares in equal tranches based on the share price trading above each of the $12.50 and $15.00 levels for 20 out of 30 trading days within three years after closing of the proposed business combination. TPB and investment funds managed by Patria Group have agreed to a two year shareholder lockup, subject to certain exceptions, with shares being released from lockup at 6, 12, 18, and 24 months. Existing Lavoro shareholders, including investment funds managed by Patria Group, will roll 100% of their equity for the first $250M in gross primary proceeds into the combined company and will own approximately 74% of the combined company after closing of the proposed business combination, assuming no redemptions. The transaction, which has been unanimously approved by the boards of directors of both Lavoro and TPB Acquisition Corp., is subject to approval by TBP Acquisition Corp.I shareholders and other customary closing conditions. The transaction is expected to close in the fourth quarter of 2022.

08:13 EDT Harte Hanks and FEVO announce expanding partnership - Harte Hanks and FEVO announced a growing partnership. The partnership is designed to help FEVO maintain its fan-and client-first ethos, as FEVO builds upon its explosive growth from 2021.The partnership expands Harte Hanks' prior successful work with FEVO to now allow Harte Hanks to serve as FEVO's exclusive CX partner. The exclusivity of this relationship demonstrates FEVO's belief in the power of best-in-class customer care that Harte Hanks provides, and the value it brings to their clients. Currently, Harte Hanks provides a range of services in support of FEVO, including client support, ticket fulfillment and back-office support. "We're excited to partner with Harte Hanks as we keep the focus on the fans and brands who trust FEVO with their purchases," said Betty Tran, FEVO Chief Marketing Officer. "To enhance our customer experience as our consumer base continues to grow, we look forward to introducing Harte Hanks' services to FEVO partners in need."

08:12 EDT Fluence Energy completes large-scale fire test for energy storage products - Fluence Energy announced the company has successfully completed a large-scale fire test for its sixth-generation energy storage products that surpassed the industry's UL9540A safety testing requirements, designed to limit the spread of a fire in energy storage deployments. Results of the large-scale fire test were issued in a report by independent engineering firm DNV, who witnessed the test as well as a separate unit-level UL9540A test.

08:10 EDT Syapse enters collaboration with Merck to better understand cancers - Syapse has entered a collaboration with Merck to leverage Syapse's leading real-world evidence solutions designed to improve outcomes for cancer patients. Merck will utilize Syapse's real-world data platform across multiple tumor types with a focus on better understanding the critical stage in the patient journey leading up to a diagnosis and beginning treatment.

08:09 EDT Corning receives $103.8M in additional funding from BARDA - Corning announced it will receive $103.8M in additional funding from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority, BARDA, in partnership with the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense and Army Contracting Command, JPEO-CBRND. The funding will support Corning's planned manufacturing expansion of advanced, high-quality pharmaceutical glass tubing and vials, helping the health care industry rapidly scale manufacturing to address current and future public health challenges. Through this planned investment in Corning's pharmaceutical glass manufacturing capacity, the U.S. government will strengthen the domestic pharmaceutical supply chain by directly addressing manufacturing efficiency constraints. Under the new agreement funded by BARDA, Corning will continue to expand pharmaceutical tubing manufacturing capacity in Vineland, New Jersey, and vial manufacturing capacity in Durham, North Carolina.

08:09 EDT Atlas Corp.'s Seaspan annuls order for four LNG containership newbuilds - Atlas' wholly-owned subsidiary Seaspan announced an update regarding contracts for four 7,700 TEU dual-fuel liquefied natural gas containership newbuildings, subject to certain closing conditions. Due to certain conditions in the contracts not being fulfilled by the counterparty, the contracts have become null and void. Seaspan has notified the relevant parties and has reserved its rights to claim against the counterparty in relation to the contracts.

08:07 EDT Arrow Electronics announces $600M share repurchase program - Arrow Electronics announced the approval by the company's board of directors of the repurchase of up to an additional $600M of common stock through its existing share repurchase program.

08:06 EDT Comtech awarded London Police Service next generation 9-1-1 contract - Comtech announced that Comtech Solacom Technologies, a division of the Company's 9-1-1 Public Safety and Security segment, was recently awarded a Next Generation 9-1-1 services contract to provide its Guardian call management solution to the London Police Services. The London Police Service is Comtech Solacom's latest customer in the Southern Ontario region, joining the Toronto Paramedic and Toronto Police Services, which also recently awarded contracts to Comtech Solacom. The new system award includes multiple years of support and comprehensive cybersecurity protection.

08:05 EDT SS&C collaborates with Trumid to expand access to corporate bond market - SS&C announced a new collaboration with Trumid, a financial technology company and fixed income electronic trading platform. Under the agreement, SS&C clients managing U.S. and emerging market corporate bonds can access Trumid through Eze OMS. Eze OMS clients can now source liquidity from Trumid's network of more than 650 buy- and sell-side institutions. The collaboration expands SS&C Eze's existing suite of connected fixed income trading platforms to six, with three more in the pipeline.

08:04 EDT Profound Medical announces changes to its management team - Profound Medical announced changes to its management team and structure designed to further position the Company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed Chief Commercial Officer - U.S. and Chief Commercial Officer - OUS, respectively, with each having overall responsibility for leading Profound's commercial strategy, sales, sales operations, and marketing activities in their corresponding geographies. They succeed Kenneth Knudson, who is leaving the Company. Goodman brings over 17 years of medical device sales experience, most recently serving as Profound's VP, U.S. Sales & Marketing. Warnken has over 20 years of experience in the medical technology industry. Before joining Profound in November 2015 as VP, International Sales & Marketing, he served as VP & General Manager Europe, Middle East, Japan and Asia Pacific, Managing Director/Officer for IMRIS Pte. Ltd., IMRIS Germany GmbH and IMRIS KK Japan.

08:04 EDT Jasper Therapeutics receives fast track designation for JSP191 - Jasper Therapeutics announced that JSP191, an anti-CD117 monoclonal antibody, has received fast track designation from the U.S. Food and Drug Administration for the treatment of patients with severe combined immunodeficiency undergoing allogeneic hematopoietic stem cell transplant. To date, JSP191 has been studied in 14 SCID patients in an ongoing multicenter clinical trial with clinical outcome data presented at academic medical conferences.

08:03 EDT Lipocine granted regulatory pathway for LPCN 1154 in post-partum depression - Lipocine announced that the FDA has agreed with Lipocine's proposal for establishing the efficacy of LPCN 1154 through a single pivotal pharmacokinetic bridge to an approved IV infusion brexanolone via a 505(b)(2) NDA filing. Lipocine plans additional work in parallel to pursue a well differentiated label. LPCN 1154 is an oral neuroactive steroid being developed for the treatment of post-partum depression. Lipocine has demonstrated that the brexanolone exposure of LPCN 1154 is similar to the levels observed in third trimester pregnant women samples. These results represent the first enablement of potentially efficacious oral brexanolone for PPD. Lipocine plans to initiate a pilot PK bridge study of LPCN 1154 and an FDA approved IV infusion brexanolone in 4Q, with results expected in 1Q23.

08:02 EDT Adobe to acquire Figma for $20B in cash and stock

07:47 EDT Innovation Pharmaceuticals announces new brilacidin antiviral data - Innovation Pharmaceuticals announced that new Brilacidin antiviral data, based on research conducted by scientists at George Mason University's Center for Infectious Disease Research, was presented at the 2022 Military Health System Research Symposium, held this week at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. "Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses."Across multiple cell lines and under different testing conditions, research showed Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus, Eastern Equine Encephalitis Virus, and Sindbis Virus. Brilacidin also was shown to inhibit Rift Valley Fever Virus, a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load. The in vitro evaluation of Brilacidin's antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin's effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes. Collectively, these data support Brilacidin's potential to be developed as a broad-spectrum antiviral. Beyond research presented at the MHSRS, Brilacidin is being studied by NIH/NIAID-affiliated researchers in different viruses. Findings from this research, as well as results from the Company's Phase 2 clinical trial of intravenous Brilacidin in hospitalized cases of moderate-to-severe COVID-19 -- which showed beneficial treatment effects -- are being prepared for publication. Three years into the COVID-19 pandemic, followed by a worldwide monkeypox outbreak, it is clear effective broad-spectrum antiviral prevention and treatment strategies are needed.

07:44 EDT Shares of Affirm and Block slip after Reuters report of CFPB regulating BNPL - Shares of Affirm (AFRM) are down 5.8% at $22.90 and those of Block (SQ), the parent company of Australia's Afterpay Ltd, are down 2.6% at $66.81 in pre-market trading following this morning's Reuters report that the U.S. Consumer Financial Protection Bureau intends to start regulating "buy-now, pay-later" firms.

07:42 EDT Pipestone Energy issues 2021 ESG report - Pipestone Energy is pleased to announce its inclusion in the 2022 TSX30 and the issuance of its 2021 Environmental, Social and Governance report. The TSX30 showcases the Toronto Stock Exchange's 30 top-performing TSX stocks over a three-year period based on dividend-adjusted share price performance. Pipestone is also pleased to announce that it has published its 2021 ESG Report, detailing the Company's ESG initiatives, activities and achievements for the year ended December 31, 2021. Pipestone's second ESG report reflects the contributions from its diverse team and provides details of Pipestone's various initiatives under the three pillars of Environment, Social and Governance. Pipestone's goal is to create a sustainable and profitable business which is respectful of the communities where we operate and limits the impact on the environment. An important achievement highlighted in our 2021 report was the independent certification of Pipestone's Montney asset by Equitable Origin Standard for Responsible Energy Development. The EO100 standard represents leading industry practices for site-level ESG performance of energy and is based on a consensus from industry, NGOs, affected communities

07:40 EDT Amesite, NAFEO announce addition of new member Universities to alliance - Amesite announces that five new member universities have joined their collaborative alliance with the National Association for Equal Opportunity in Higher Education, NAFEO. New members include: Alabama State University; Allen University; Benedict College; Clark Atlanta University; University of the District of Columbia. The new members have agreed to join NAFEO's Center for Opportunity and Equity, a vehicle that NAFEO intends to support with a $30M fundraising effort to bring online learning resources to a first group of NAFEO's constituents, including Historically Black Colleges and Universities and Predominantly Black Institutions. Amesite Founder & CEO Dr. Ann Marie Sastry commented, "We are thrilled with the speed that this alliance within NAFEO is growing, honored to serve as their technology, content and services provider, and believe that it will lead to exponential growth in Amesite's ability to serve NAFEO's 106 member HBCUs and 81 PBIs. We are delighted to support this ambitious effort with our enterprise-scale platform, and expect to be extremely active in setting up services and delivering learning, as NAFEO gathers resources to support vitally needed online programs."

07:38 EDT K92 Mining announces inclusion in 2022 TSX30 - K92 Mining announced that is has been included in the Toronto Stock Exchange's 2022 TSX30, a flagship program recognizing the 30 top-performing stocks over a three-year period based on dividend-adjusted share price appreciation. KNT ranked 11th on the 2022 list based on a share price appreciation of 337% over the three-year period.

07:38 EDT IBI Group announces inclusion in 2022 TSX30 - IBI Group is pleased to share that the Company has been included in the 2022 TSX30, the Toronto Stock Exchange's flagship program showcasing the 30 top-performing stocks over a three-year period, based on dividend-adjusted share price performance. During this three-year period, the value of IBI's share price increased by 188%, and has risen a further 34% since June 30, 2022 following the proposed acquisition of IBI by Netherlands-based Arcadis for $19.50 per share in cash, announced July 18, 2022.

07:37 EDT Humana jumps 5% to $481.00 after raising FY22 EPS view

07:36 EDT Adobe down about 3% in pre-market after Bloomberg report of potential Figma deal

07:34 EDT In8bio partners with Dunbar CAR T-Cell program at UofL - IN8bio announced it has selected the University of Louisville, UofL, Health - Brown Cancer Center GMP Manufacturing Facility at the University of Louisville, home of the Dunbar CAR T-Cell Program, as its manufacturing partner for INB-400. The collaboration provides IN8bio exclusive access to a state-of-the-art GMP manufacturing facility and is structured to support the Company's anticipated INB-400 Phase 2 clinical program in glioblastoma. "One of the biggest challenges facing cell therapy companies is efficient access to high-quality manufacturing facilities with the experience and capacity required to support multicenter clinical trials and commercial manufacturing," said Kate Rochlin, Ph.D., Chief Operating Officer of IN8bio. "The Dunbar CAR T-Cell Program has a superb facility designed specifically to advance the development of promising T-cell therapies. We are excited to progress our INB-400 program towards a Company sponsored investigational new drug application that will advance this program into Phase 2."

07:33 EDT ZW Data Action Technologies announces planned acquisition of Henan Baodun - ZW Data Action Technologies announced that it has signed a letter of intent, LOI, and has formally proposed an acquisition offer to Henan Baodun Information Technology. Pursuant to the LOI, the offer price and terms will be negotiated and determined upon completion of due diligence, and the completion of the transaction is envisaged in the fourth quarter of 2022. Upon the completion of the acquisition, Baodun will become a wholly-owned subsidiary of the Company, and will remain its independency in operation to provide one-stop eCommerce marketing service solutions and full agency operation services for customers. The strategic acquisition of Baodun is intended to enhance ZW Data's competitiveness within the industry and especially in the short video platform market. The Company expects that this acquisition will drive a meaningful increase in short and long-term ZW Data's revenue. "We are excited to announce this planned acquisition of Baodun. The short video market has expansive development prospect, and nowadays, social media platforms such as TikTok and Kuaishou have billions of users domestically and internationally. The elite veterans of Baodun are primarily located in Zhengzhou, Henan Province and Guangzhou, Guangdong Province. We are extremely thrilled that the founder of Baodun, Ms. Ning Lv, as one of the most experienced ECommerce operators in China, will join the Company with the management team upon the completion of the transaction. The addition of the new team will accelerate the development of our short video merchandising capabilities and reinforce our commitment to building a leading merchandising enterprise in China. We believe that this acquisition will drive the diversification of our business, form a new profit growth point, and enhance the profitability to bring near and long-term values for shareholders," commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data.

07:20 EDT Charge Enterprises appoints Jeffrey Kuhlman as CCO - Charge Enterprises announced that Jeffrey Kuhlman has joined the Company as Chief Communications Officer handling public relations, corporate communications, and marketing. Kuhlman joins Charge from Bentley Motors, where he was Chief Communications & Marketing Officer.

07:17 EDT Gamesquare Esports names Jill Peters as COO, Paolo DiPasquale as CSO - GameSquare Esports announced that the Company has added new members to its team to support accelerating revenue growth, while further optimizing its businesses. New hires include the roles of Chief Operating Officer, Chief Strategy Officer, Regional Sales Directors, and Social Media Lead. Additionally, the Company has created a Head of Partnerships and Brand Experience position, which has been filled internally. Jill Peters, Chief Operating Officer, GameSquare. Jill has a proven track record of managing early-stage start-ups, hyper-growth scaling, and turn-around phases of companies. Paolo DiPasquale, Chief Strategy Officer, Gamesquare. Mr. DiPasquale has more than 16 years of capital markets experience in investment banking, equity research, and institutional equity. Mr. DiPasquale was instrumental in developing and implementing the gaming and esports strategy and capital market presence at Canaccord Genuity. Bee Yancey, Head of Partnerships and Brand Experience, GameSquare. Ms. Yancey has more than 15 years experience executing partnership marketing initiatives and designing corporate hospitality programs, Jessey Finizio, Vice President, Sponsorship Sales, Complexity Gaming. Prior to joining Complexity Gaming, Jessey held the position of Director, Client Strategy at Twitch, an Amazon company, and was VP, Client Partnerships at VICE Media Group. Jon "Blackbeard" Schmid, Senior Social Media Manager, Complexity Gaming. Blackbeard was most recently Senior Social Media Manager at 100 Thieves and has held various social media roles at OpTic Gaming and Infinite Esports & Entertainment. Stephanie Cohen, Senior Director, Brand Partnerships, GCN. Stephanie's professional experience includes agency experience at Spark and Mindshare Chicago, and digital sales experience at Conde Nast and Apartment Therapy Media. Jack McAuliffe, Senior Director of West Coast Sales, GCN. Mr. McAuliffe has spent the past 10 years working in digital media sales on the West Coast for Rodale, publisher of Men's Health, Women's Health, and Runner's World, and Future US where he specialized in sales for technology and gaming properties including Tech Radar, Tom's Guide, PC Gamer, and GamesRadar.

07:13 EDT OTC Market Group welcomes EverGen Infrastructure to OTCQX - OTC Markets Group announced EverGen Infrastructure Corp has qualified to trade on the OTCQX Best Market. EverGen Infrastructure Corp. upgraded to OTCQX from the OTCQB Venture Market.

07:11 EDT DynaEnergetics launches IS2 Xpress upgrade - DynaEnergetics introduced IS2 Xpress, a significant upgrade to the core initiating technology used in DynaEnergetics' DS well perforating systems. IS2 Xpress builds upon DynaEnergetics' revolutionary IS2 TF Intrinsically Safe Initiating System, a wirefree integrated switch detonator that brought unmatched safety and reliability to the oil and gas well perforating process. The IS2 Xpress is based on the same technological platform, but provides greater consistency and near-instant readiness between initiations across an entire perforating string. This responsiveness can significantly reduce the time required to perforate a well.

07:09 EDT Emerita announces additional assay results from drilling at La Romanera - Emerita Resources announce additional assay results from the 2022 exploration drilling at its La Romanera Deposit on the Iberian Belt West, IBW, project. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. All deposits are open for expansion along strike and at depth. The current results are from 3 drill holes in La Romanera LR012, LR014 and LR017. All three holes intercepted the Upper and Lower lenses. Presently, there are 9 diamond drills delineating the Romanera deposit and one rig continues to drill the La Infanta deposit.

07:08 EDT CI Financial reports August AUM of $345.9B - CI Financial reported preliminary total assets of $345.9B as at August 31, consisting of asset management assets of $119B, Canadian wealth management assets of $76.6B, and U.S. wealth management assets of $150.4B.

07:07 EDT Skylight Health expands value-based-care plan in Florida - Skylight Health Group provides an update on the expansion of one of its current Medicare Advantage, MA, plans from South Florida into Central Florida, increasing value-based care coverage. Skylight is currently contracted with Florida MA provider in South Florida; Its new amendment expands the current contract into its 3 primary care practices in Central Florida starting January 2023; The expansion of its current AvMed contract allows Skylight to begin enrolling Medicare members currently in the Central Florida market; Skylight expects the expanded coverage to contribute growth in MA membership for 2023. Skylight Health continues to see opportunities to expand current and engage with new provider partners for MA value-based care across its network in Florida. The Company currently has 4 MA value-based care contracts in place with future contracts in negotiation. Additionally, the amendment to expand coverage also includes a shift in the current reimbursement model from fee-for-service to a value-based care capitation fee with shared savings opportunities. The Company expects that credentialing will be completed in time for annual enrollment that generally runs between October and December of each calendar year. This would enable its 3 central Florida locations to begin accepting new MA members under this plan for an effective start in January 2023. The Company is actively working on additional MA plans for 2023 and looks forward to announcing further updates on these agreements in the coming weeks ahead. The company has granted an aggregate of 220,000 stock options and 167,500 RSU's to officers, and employees of the Company in accordance with the Company's incentive stock option plan, subject to regulatory acceptance. These incentive stock options are exercisable at $0.67 per share for a period of three years. Pursuant to the terms and subject to the conditions of the Debt Settlement Agreements, the Company will issue an aggregate of 738,080 common shares to the Creditors at a deemed price of $0.70 per Common Share, in satisfaction of the Debt. The issuance of the Common Shares to the Creditors pursuant to the Debt Settlement Agreement is subject to the approval of the TSX Venture Exchange.

07:06 EDT Aptorum updates clinical validation of RPIDD technology in patient samples - Aptorum Group announced further updates on the analytical and both the retrospective and prospective clinical validation of the RPIDD technology in patient samples, employed under both Illumina iSeq 100 and MiniSeq sequencing platforms. RPIDD, using its proprietary developed depletion and enrichment technologies, has been clinically validated in over 100 patient samples so far. In the completed retrospective clinical validation, both iSeq 100 and MiniSeq employing the RPIDD workflow demonstrated a 100% agreement with positive clinical data in identifying the causative pathogen . In addition, under both iSeq 100 and MiniSeq platforms, RPIDD also showed a 100% agreement with the negative clinical molecular diagnosis data on the relevant clinical samples. In our prospective clinical validation of RPIDD, patients have been enrolled with febrile neutropenia and sepsis conditions and that over 50 samples have been collected and analyzed. The trial is still ongoing but so far general agreement has been observed compared with standard of care diagnostics results such as blood culture technology and/or PCR. Various bacteria and both DNA and RNA viruses have been detected in these patient samples, including Hepatitis B and C virus, Cytomegalovirus, Epstein-Barr virus, Human Immunodeficiency virus, Dengue, Escherichia coli, Klebsiella pneumoniae and Herpesviridae, etc. In the analytical validations of RPIDD, it has also been demonstrated that analytical sensitivity of 100% in MiniSeq and 92.5% in iSeq 100 in the low-depth low-cost sequencing assay, and analytical specificity of more than 95.0% in MiniSeq.

07:05 EDT Anterix partners with Future Technologies for private wireless networks - Anterix and Future Technologies have launched an alliance to integrate Anterix's 900 MHz spectrum with Future Technologies' end-to-end digital transformation solutions. The new cooperative effort responds to interest in private wireless networks to address valuable use cases in select vertical markets, including oil & gas, chemical, government, manufacturing, logistics, aerospace, mining, and smart agriculture. Anterix is focused on enabling private LTE and 5G networks for utilities. Future Technologies is a specialized Lead System Integrator that provides industry 4.0 and mission critical solutions to their greater than180 customers by specializing in the assessment, planning, design, implementation, and support of innovative communications solutions.

07:03 EDT CSX appoints Hinrichs as President, CEO - CSX (CSX) announced that, as part of a planned succession process, its Board of Directors has appointed seasoned executive Joseph Hinrichs as the Company's new President and Chief Executive Officer, CEO, effective September 26, 2022. Hinrichs succeeds James Foote, who plans to retire as President and Chief Executive Officer, as well as from the Board, on September 26, 2022. Foote will continue to work with the Company through March 31, 2023 as an advisor to facilitate a seamless leadership transition. Hinrichs has more than 30 years' experience in the global automotive, manufacturing, and energy sectors, previously serving as President of Ford Motor's (F) automotive business.

07:02 EDT Tiziana Life Sciences announces grant received by BWH - Tiziana Life Sciences announces that a Lawrence & Isabel Barnett Drug Development Program Grant will be awarded to the Ann Romney Center for Neurologic Diseases at the Brigham and Women's Hospital, BWH, by the ALS Association for the study of an intranasal anti-CD3 monoclonal antibody, mAb, in an animal model of Amyotrophic Lateral Sclerosis, ALS. Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "Intranasal foralumab has demonstrated potential across multiple Central Nervous System indications. We are encouraged by the preclinical research using an intranasal anti-CD3 mAb in the neuroinflammatory related diseases of ALS and Alzheimer's, as well as the impressive clinical benefits we have already shown for foralumab in patients with multiple sclerosis. While our initial focus is on our ongoing MS program which will continue to generate clinical read-outs, we are excited by foralumab's potential to help highly debilitated ALS patients with limited therapeutic options and high unmet need."

06:49 EDT Pfizer's meningococcal vaccine meets Phase 3 immunogenicity, safety endpoints - Pfizer announced "positive" top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine - MenABCWY - in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints, with the investigational vaccine demonstrating non-inferiority to licensed vaccines for the five meningococcal serogroups that cause the majority of invasive meningococcal disease. Currently, MenACWY and MenB vaccines are licensed separately, and no single vaccine is available to help protect against the five serogroups. In individuals who had not previously received a meningococcal vaccine, the proportion of subjects with greater than or equal to4-fold increases in immune responses was observed to be higher following either one or two doses of MenABCWY for serogroups A, C, W and Y vs. one dose of Menveo. The pentavalent vaccine candidate was well-tolerated, with a safety profile consistent with licensed vaccines. Based on these Phase 3 results, which meet pre-determined criteria for licensure, Pfizer intends to submit a Biologics License Application to the FDA in Q4. Submissions to additional regulatory authorities outside the U.S. are also planned.

06:36 EDT Samsung to invest over KRW 7T in environmental initiatives by 2030 - Samsung Electronics announced its new environmental strategy, a comprehensive effort to join global efforts to tackle climate change. The company said, "It includes commitments to achieve enterprise-wide net zero carbon emissions and plans to use more renewable energy, as well as to invest in and research new technologies to develop energy-efficient products, increase water reuse and develop carbon capture technology. At the heart of the new commitment is achieving net zero carbon emissions for all operations in the Device eXperience Division by 2030, and across all global operations, including the Device Solutions Division, by 2050. The DX Division encompasses the company's consumer electronics businesses, including Mobile eXperience, Visual Display, Digital Appliances, Networks and Health & Medical Equipment, while the DS Division includes the Memory, System LSI and Foundry businesses. Samsung Electronics has also joined RE100, a global initiative dedicated to pursuing 100 percent renewable energy. As part of this commitment, the company plans to match electric power needs of all international markets where it operates, outside of Korea, with renewable energy within five years. The new plan builds on Samsung Electronics' existing climate efforts, significantly expanding the scope of its programs and investments. Samsung will develop new technologies and implement further sustainable practices to enable a brighter future for all." In recognition of the need for innovative approaches around environmental sustainability, Samsung Electronics will invest over KRW 7 trillion in its environmental initiatives by 2030, including reducing process gases, conserving water, expanding electronic waste collection and reducing pollutants. The investment figure excludes costs related to expansion of renewable energy use. Reference Link

06:26 EDT Walmart introduces virtual fitting room for apparel - In a blog post, Denise Incandela, EVP, apparel and private brands for Walmart U.S., said, "We are continuing to make bold moves to establish Walmart as a destination for fashion. It started with work over the last few years to expand our assortment of quality, on-trend and accessible apparel and accessories. More recently, it includes prioritizing the creation and introduction of innovative shopping experiences that help customers discover the assortment and enable new and existing customers to shop with confidence. The acquisition and implementation of the Zeekit virtual try-on platform are a huge part of that strategy. Earlier this year, we introduced the first implementation of the game-changing technology Choose My Model, which was met with terrific customer response. Today, we are embarking on the next phase of our virtual try-on technology with Be Your Own Model, industry leading technology that brings the in-store fitting room experience to online shoppers. This experience allows customers to use their own photo to better visualize how clothing will look on them, and creates a gamification of shopping that we believe will be very compelling to the customer. Walmart is the first to offer a virtual try-on experience for apparel brands at scale, and it's the most realistic application I have seen." Reference Link

06:09 EDT BrainStorm announces NurOwn trial data published in Multiple Sclerosis Journal - BrainStorm announced the peer reviewed publication of data from the Phase 2 trial of NurOwn in progressive multiple sclerosis, or MS, in Multiple Sclerosis Journal. Results from the Phase 2, single-arm, open-label study demonstrated NurOwn's safety and provided preliminary evidence of its efficacy in people with progressive MS. Additionally, biomarker analyses confirmed NurOwn's proposed mechanism of action by showing consistent treatment effects in neuroinflammation and neuroprotection pathways. Twenty participants were enrolled into the Phase 2 trial, with seventeen receiving all three scheduled NurOwn treatments. The mean age of study participants was 47 years with a mean expanded disability status scale, or EDSS, score of 5.4 at screening. Results from the trial were compared to 48 matched control patients who were selected from the from the Comprehensive Longitudinal Investigation of Multiple Sclerosis, or CLIMB, registry at the beginning of the trial. Treatment with NurOwn resulted in large, clinically meaningful improvements in some patients, as defined by response criteria, across all endpoints measured. These endpoints included timed 25-foot walk speed, 9-hole peg test, multiple sclerosis walking scale, symbol digit modality test and low contrast letter acuity. These observed improvements diverged from what was seen in matched patients with progressive MS from the CLIMB registry. Key data from the trial, as well as relevant comparisons to the matched CLIMB registry patients, are shown below. In total, 19% of treated trial participants were responders, compared to 4% of the matched CLIMB registry patients; 38% of treated trial participants showed a 10-point improvement from baseline in the 12-item MSWS; 27% of treated trial participants showed a =8-letter improvement in LCLA binocular at a 2.5% contrast threshold, compared to 6% of the matched CLIMB registry patients; 67% of treated trial participants showed a 3-point improvement in the SDMT, compared to 18% of the matched CLIMB registry patients; 47% of treated trial participants showed a 8-point improvement in LCLA binocular at a 1.25% contrast threshold. Across all participants, improvements in function as measured by LCLA, SDMT and MS Functional Composite were observed. Mean improvements from baseline of 3.3 points in the LCLA binocular, 3.8 points on the SDMT, and 0.18 points in MSFC were observed in treated trial participants. The corresponding changes in matched CLIMB registry patients estimated at 28 weeks showed declines in function on the LCLA and MSFC. The average change in function decline as measured by T25FW, 9HPT, and EDSS across all treated trial participants demonstrated stabilization of functional decline, with similar or slightly worse findings observed in the matched CLIMB registry patients for the same endpoints.There were no adverse events related to worsening of MS disease and no clinically significant changes in safety lab results/vital signs, confirming NurOwn's favorable safety profile. Two patients developed symptoms of low back and leg pain, consistent with arachnoiditis, occurring in one of three treatments in both participants.Treatment also consistently resulted in increases in cerebrospinal fluid neuroprotective factors and reductions in inflammatory biomarkers, confirming NurOwn's proposed mechanism of action in progressive MS.

06:05 EDT China Yuchai wins order for 100 heavy-duty truck engines from Jianghuai - China Yuchai announced it won an order for 100 heavy-duty truck engines from Jianghuai Heavy Duty Truck. This large order is mainly for Yuchai's YCK08 and YCK11 engines to power JAC HD Truck's 84 heavy-duty trucks and dump trucks as well as JAC HD Truck's 64 semi-trailers. Additionally, Yuchai's YCK11 and YCK12 engines will also power JAC HD Truck's 64 semi-trailers. These vehicles are expected to be deployed in Anhui, Jiangsu, Shandong and Hebei Provinces, and other key domestic logistics areas. The partnership with JAC HD Truck has a long history and now is extending to National VI-compliant models YCS04, YCK05, YCS06, YCK08, YCK11 and YCK12 diesel engines.

06:03 EDT Goldman Sachs AM, Cleanhill Partners acquire majority stake in EPC Power Corp. - EPC Power Corp. announced the Sustainable Investing business within Goldman Sachs Asset Management and Cleanhill Partners have acquired a majority stake in its company. The strategic investment, along with a comprehensive recapitalization, positions EPC Power to expand and deliver against rapid growth in the renewable energy storage markets while helping facilitate the U.S. economy's clean energy transition. The transaction closely follows the signing into law of the Inflation Reduction Act of 2022, which among other provisions extends a first-ever tax credit to stand-alone energy storage, creating a significant financial incentive for adopting EPC Power's inverters and other technologies. EPC Power is the only U.S.-based, end-to-end power conversion solution provider, making its technology well-suited for grid-scale applications that require added layers of security.

05:40 EDT Ford introduces 2024 Mustang, sticks with gasoline engine - Ford introduced the all-new Ford Mustang. The seventh generation has a fighter jet-inspired digital cockpit, a new advanced turbocharged and naturally aspirated engines. "Investing in another generation of Mustang is a big statement at a time when many of our competitors are exiting the business of internal combustion vehicles," said Jim Farley, CEO of Ford Motor Company. "Ford, however, is turbocharging its ICE growth plan, adding connected technology, opinionated derivatives, and hybrid options to our most profitable and popular cars - all in the Ford Blue family - on top of investing $50 billion in electric vehicles through 2026." The all-new Mustang goes on sale in the U.S. starting in the summer of 2023 and is assembled at Flat Rock Assembly Plant in Flat Rock, Michigan.

05:20 EDT President Biden says tentative railway labor agreement has been reached - President Biden announced that a tentative railway labor agreement has been reached. The President said: " It is a win for tens of thousands of rail workers who worked tirelessly through the pandemic to ensure that America's families and communities got deliveries of what have kept us going during these difficult years. These rail workers will get better pay, improved working conditions, and peace of mind around their health care costs: all hard-earned. The agreement is also a victory for railway companies who will be able to retain and recruit more workers for an industry that will continue to be part of the backbone of the American economy for decades to come. I thank the unions and rail companies for negotiating in good faith and reaching a tentative agreement that will keep our critical rail system working and avoid disruption of our economy." Publicly traded companies in the rail space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) and Union Pacific (UNP).

05:18 EDT Sylvamo to acquire Stora Enso uncoated freesheet paper mill in Sweden for $150M - Sylvamo announced it agreed to acquire Stora Enso's uncoated freesheet paper mill in Nymolla, Sweden, for approximately $150M expected to be funded in cash, subject to customary purchase price adjustments. The agreement includes the mill, the brands it produces and the people who make it happen. The integrated mill has two pulp lines and the capacity to produce approximately 500,000 short tons of uncoated freesheet on two paper machines. In the last 12 months ending June 30, the facility generated 350M euros in revenue. The mill produces several brands, including Multicopy, and paper used for office printing, business forms, digital printing, offset for printing books and much more. The mill generates 85% of its energy needs from carbon-neutral, renewable biomass residuals. Stora Enso leaders and team members who operate and support the mill will bring their expertise to Sylvamo. The transaction is expected to close no later than the first quarter of 2023 and is subject to customary closing conditions, including receiving the required regulatory approvals.

05:13 EDT Broadridge announces integrated trading solution partnership with Coinbase - Broadridge (BR) has announced a partnership with Coinbase (COIN), offering interoperability between Coinbase Prime and Broadridge Trading and Connectivity Solutions' NYFIX order-routing network. Coinbase Prime is a solution that provides a trading platform, secure custody and prime services to manage crypto assets in one place. Coinbase Prime offers aggregated access to the majority of the market's crypto liquidity via a smart order router and also provides full prime brokerage capabilities to the buy-side. This solution allows NYFIX clients to route order flow to Coinbase Prime via the FIX protocol. It also allows buy-side traders to source crypto liquidity from Coinbase and trade right from their OMS. The solution is now offered to U.S. domestic clients and will roll out to additional regions as regulations allow.